WST West Pharmaceutical Services Inc

Price (delayed)

$329.72

Market cap

$24.44B

P/E Ratio

41.9

Dividend/share

$0.74

EPS

$7.87

Enterprise value

$23.87B

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, ...

Highlights
West Pharmaceutical Services's quick ratio has increased by 28% YoY
WST's equity is up by 15% year-on-year and by 9% since the previous quarter
The stock's price to earnings (P/E) is 23% more than its last 4 quarters average of 34.2 but 10% less than its 5-year quarterly average of 46.4
WST's debt is up by 6% since the previous quarter but it is down by 2.3% year-on-year
WST's EPS is down by 11% year-on-year and by 7% since the previous quarter
The net income has contracted by 11% YoY and by 7% from the previous quarter

Key stats

What are the main financial stats of WST
Market
Shares outstanding
74.14M
Market cap
$24.44B
Enterprise value
$23.87B
Valuations
Price to earnings (P/E)
41.9
Price to book (P/B)
9.09
Price to sales (P/S)
8.5
EV/EBIT
33.69
EV/EBITDA
28.79
EV/Sales
8.27
Earnings
Revenue
$2.89B
EBIT
$708.5M
EBITDA
$829.1M
Free cash flow
$439.4M
Per share
EPS
$7.87
Free cash flow per share
$5.91
Book value per share
$36.27
Revenue per share
$38.8
TBVPS
$46.92
Balance sheet
Total assets
$3.62B
Total liabilities
$931.9M
Debt
$317.9M
Equity
$2.68B
Working capital
$1.4B
Liquidity
Debt to equity
0.12
Current ratio
3.7
Quick ratio
2.7
Net debt/EBITDA
-0.7
Margins
EBITDA margin
28.7%
Gross margin
39.4%
Net margin
20.3%
Operating margin
25.4%
Efficiency
Return on assets
17.2%
Return on equity
23.7%
Return on invested capital
30.7%
Return on capital employed
22.9%
Return on sales
24.5%
Dividend
Dividend yield
0.22%
DPS
$0.74
Payout ratio
9.4%

WST stock price

How has the West Pharmaceutical Services stock price performed over time
Intraday
-1.99%
1 week
4.82%
1 month
5.1%
1 year
-18.64%
YTD
40.1%
QTD
40.1%

Financial performance

How have West Pharmaceutical Services's revenue and profit performed over time
Revenue
$2.89B
Gross profit
$1.14B
Operating income
$734M
Net income
$585.9M
Gross margin
39.4%
Net margin
20.3%
WST's net margin is down by 13% year-on-year and by 6% since the previous quarter
The net income has contracted by 11% YoY and by 7% from the previous quarter
The operating margin has declined by 6% since the previous quarter and by 4.5% year-on-year
WST's operating income is down by 6% from the previous quarter and by 2.4% YoY

Growth

What is West Pharmaceutical Services's growth rate over time

Valuation

What is West Pharmaceutical Services stock price valuation
P/E
41.9
P/B
9.09
P/S
8.5
EV/EBIT
33.69
EV/EBITDA
28.79
EV/Sales
8.27
The stock's price to earnings (P/E) is 23% more than its last 4 quarters average of 34.2 but 10% less than its 5-year quarterly average of 46.4
WST's EPS is down by 11% year-on-year and by 7% since the previous quarter
WST's equity is up by 15% year-on-year and by 9% since the previous quarter
The P/S is 15% above the 5-year quarterly average of 7.4 and 10% above the last 4 quarters average of 7.7

Efficiency

How efficient is West Pharmaceutical Services business performance
West Pharmaceutical Services's ROE has decreased by 25% YoY and by 10% from the previous quarter
The company's return on assets fell by 21% YoY and by 9% QoQ
WST's return on invested capital is down by 19% year-on-year and by 9% since the previous quarter
WST's return on sales is down by 11% year-on-year and by 6% since the previous quarter

Dividends

What is WST's dividend history
DPS
$0.74
Dividend yield
0.22%
Payout ratio
9.4%
Recent dividends

Financial health

How did West Pharmaceutical Services financials performed over time
West Pharmaceutical Services's quick ratio has increased by 28% YoY
West Pharmaceutical Services's current ratio has increased by 26% YoY but it has decreased by 2.6% QoQ
WST's debt is 88% smaller than its equity
WST's equity is up by 15% year-on-year and by 9% since the previous quarter
The debt to equity has contracted by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.